Preclinical studies have demonstrated that antibodies blocking TIGIT plus PD-L1 or TIM-3 simultaneously can specifically enhance the effector function of CD8+ T-cells, leading to significant anti-tumour immune response (112, 113). The gene discussed is CD8A; the disease is neoplasm.